UMCCR seminar: Seeing Patterns: The value of studying hereditary cancer

Wednesday 27 March 2019 | Melbourne   This UMCCR seminar by Dr Ian Frayling, Consultant in Genetic Pathology, Institute of Medical Genetics, University Hospital of Wales, will be held on Wednesday 27 March 2019 at the Victorian Comprehensive Cancer…

Read More

Seminar: Unlocking the potential of cochlear stem cells to regenerate the inner ear

Friday 22 March 2019 | East Melbourne   The next seminar in The Bionics Institute Seminar Series will be held on Friday 22 March from 4.00–5.00pm at The Bionics Insitute in East Melbourne. Dr Niliksha Gunewardene from The Bionics Institute…

Read More

UMCCR seminar: Dr Andrew Pattison and Priscilla Gates

Wednesday 20 March 2019 | Melbourne  The next seminars in the University of Melbourne Centre for Cancer Research will be held on Wednesday 20 March from 10.30–11.30 am at the Victorian Comprehensive Cancer Centre. For more information and to…

Read More

Webinar: Permitted indications for listed medicines

25 March 2019 | Online  SME Assist is holding a webinar to help you understand how to use permitted indications with listed medicines. The session is recommended for small to medium enterprises or sponsors who are unfamiliar with…

Read More

Media release: Victorian medtech startups to get strategy boost for entering the US healthcare market

14 March 2019 | A new program to help Victorian medtech startups enter the US market is being launched next week in Melbourne. Healthtech Reimbursement: Getting Paid in the USA has been developed by BioMelbourne Network, with support…

Read More

New space for Outerspace Melbourne

8 March 2019 | Outerspace Melbourne has settled in the new makerspace in Abbotsford, a short drive from the old studio. The team enjoyed designing the “clean slate” space and making it their own, with an open layout…

Read More

Immutep presents positive IMP761 preclinical results

8 March 2019 | Immutep today announced positive results from its preclinical study of IMP761, a novel LAG3 agonist antibody being developed for the treatment of autoimmune diseases. The results were presented at the 14th Congress of European…

Read More

Immutep doses first patient in TACTI-002 Phase II trial

8 March 2019 | Immutep has just announced that the first patient has been dosed in a new Phase II clinical trial (TACTI-002) which will evaluate the combination of their lead product candidate, eftilagimod alpha (“efti”), and KEYTRUDA®…

Read More

Immutep announces data from ongoing TACTI-mel Phase I clinical trial in unresectable or metastatic melanoma

8 March 2019 | This week at the World Immunotherapy Congress 2019 in San Diego USA, Immutep announced positive, more mature data from its ongoing TACTI-mel phase I clinical study of the company’s lead product candidate, eftilagimod alpha…

Read More


News & opinion

Member Directory